Hansoh Pharmaceutical Group (HKG:3692) subsidiaries Shanghai Hansoh Biomedical and Jiangsu Hansoh Pharmaceutical Group signed a global license deal for their diabetes and weight loss drug candidate, HS-10535, according to Hong Kong bourse filing Wednesday.
A Merck Sharp & Dohme subsidiary will pay up to $2 billion to acquire the global license to develop, manufacture, and commercialize HS-10535, which includes a $112 million upfront payment and up to $1.9 billion in milestone payments, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments